Abstract
The efficacy and safety of a new tumor necrosis factor inhibitor, certolizumab pegol, in active rheumatoid arthritis has now been assessed in three phase III, multicenter, randomized, double-blind, placebo-controlled clinical trials. This commentary focuses on the paper by Keystone et al., in which patients were followed for the longest duration. This study, which compared two doses of subcutaneous certolizumab pegol with placebo in patients with active RA receiving methotrexate, showed no advantage of 400 mg over 200 mg certolizumab pegol over 52 weeks, after induction with 400 mg. The nature of the patients enrolled in this study, trial design and possible safety issues are discussed, as is whether this trial can teach us anything about tumor necrosis factor inhibitors in general. On the basis of the results from this study, certolizumab pegol does not represent a major addition to our armamentarium, but because of the slightly different mechanism of action and structure of this drug, and the apparently acceptable therapeutic effects over one year, it is, nevertheless, welcome.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Furst DE et al. (2008) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 67 (Suppl 3): iii2–iii25
Nesbitt A et al. (2007) Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 13: 1323–1332
Smolen JS et al. (2008) Efficacy and Safety of Certolizumab Pegol Plus Methotrexate in Active Rheumatoid Arthritis: The RAPID 2 Study. Ann Rheum Dis. [10.1136/ard.2008.101659]
Keystone E et al. (2008) Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 58: 3319–3329
Fleischmann R et al. (2008) Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis. [10.1136/ard.2008.099291]
Author information
Authors and Affiliations
Ethics declarations
Competing interests
D Furst has acted as a consultant and has received grant/research support (including clinical trials) from Abbott, Amgen, Centocor and UCB.
Rights and permissions
About this article
Cite this article
Furst, D. Certolizumab pegol—what role does this new TNF inhibitor have in the treatment of RA?. Nat Rev Rheumatol 5, 134–135 (2009). https://doi.org/10.1038/ncprheum1004
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum1004